Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study-Reference-Cited by-同舟云学术

Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study

Published:2020-03-13 Issue:6 Volume:104 Page:581-587
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Iannitto Emilio¹^ORCID,Romano Alessandra²,Scalzulli Potito Rosario³,Bonanno Vincenza¹,Scalone Renato¹,Chiarenza Annalisa²,Pirosa Maria Cristina²,Caruso Anastasia Laura²,Minoia Carla⁴,Mantuano Saverio³,De Santis Gaetano⁵,Salerno Marilena⁶,Crescimanno Alessandra¹,Porretto Ferdinando¹,Li Gioi Felicina⁷,Ricciuti Giuseppina³,Greco Antonino⁸,Pavone Enzo⁸,Guarini Attilio⁴,Tarantini Giuseppe⁵,Mannina Donato⁷,Consoli Ugo⁶,Cascavilla Nicola³,Di Raimondo Francesco²,Musso Maurizio¹

Affiliation:

1. Department of Oncology, Hematology and BMT Unit Casa di Cura La Maddalena Palermo Italy

2. Division of Hematology AOU Policlinico Department of Surgery and Medical Specialties University of Catania Catania Italy

3. UOC di Ematologia Casa di Cura Sollievo della Sofferenza San Giovanni Rotondo Italy

4. IRCCS Istituto Tumori Giovanni Paolo II Bari Italy

5. UOC Ematologia Ospedale Dimiccoli Barletta Italy

6. UOC di Ematologia Ospedale Garibaldi‐Nesima Catania Italy

7. UOC di Ematologia Azienda Ospedaliera Papardo Messina Italy

8. UOC di Ematologia Azienda Ospedaliera Pia Fondazione Cardinale Giovanni Panìco Tricase Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13400

Reference47 articles.

1. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease

2. Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

3. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT

4. FDG PET/CT imaging as a biomarker in lymphoma

5. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody based therapies in Hodgkin lymphoma;Cancer Treatment Reviews;2024-01

2. Advances in the treatment of Hodgkin's lymphoma (Review);International Journal of Oncology;2023-04-04

3. Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?;Cancers;2022-07-20

4. Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review;Cureus;2022-03-24

5. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma;Pediatric Blood & Cancer;2022-02-02